Related references
Note: Only part of the references are listed.Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad concept
Louis Monnier et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2009)
Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2009)
Type 2 diabetes: A well-characterised but suboptimally controlled disease. Can we bridge the divide?
L. Monnier et al.
DIABETES & METABOLISM (2008)
Rosiglitazone no longer recommended
[Anonymous]
LANCET (2008)
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The burden of treatment failure in type 2 diabetes
JB Brown et al.
DIABETES CARE (2004)
Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor.: The DECODE Study
B Balkau et al.
DIABETOLOGIA (2004)
The treat-to-target trial - Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients
MC Riddle et al.
DIABETES CARE (2003)
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
IM Stratton et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
Share Paper
